The 'crucial' growth metric that makes CSL shares a buy today

A leading expert points to a critical growth metric that could boost CSL shares in 2025.

| More on:
Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares can't escape the wider market sell-down today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock are down 0.22% in afternoon trade on Wednesday, changing hands for $264.12 apiece.

For some context, the ASX 200 is down 0.84% at this same time.

But looking to the year ahead, Ord Minnett's Tony Paterno has an optimistic outlook on CSL stock (courtesy of The Bull).

Time to buy CSL shares?

"This biotechnology giant recently posted mixed results across its key business units in the first half of fiscal year 2025," said Paterno, who has a buy recommendation on CSL shares.

But a crucial growth metric could be set to boost the company's profitability.

According to Paterno:

Management flagged that gross margins for its plasma business Behring are expected to reach about 57% by fiscal year 2027/2028. We believe this is crucial considering Behring currently accounts for about 67% of group revenue and 63% of earnings.

Commenting on the ongoing effort to boost gross margins after CSL released its H1 FY 2025 results last month, CEO Paul McKenzie said, "In CSL Behring we will continue to focus on improving our gross margins, which will be aided by the expected completion of the RIKA roll-out across CSL Plasma by the end of the financial year."

Rounding off why he's bullish on the ASX 200 biotech stock, Paterno noted, "Recent price/earnings valuations imply an attractive entry level, particularly as CSL has traditionally traded at a steep premium to the S&P/ASX200."

CSL stock also trades on an unfranked dividend yield (part trailing, part pending) of 1.6%.

But not everyone is convinced that now is the best time to pull the trigger on CSL shares.

A more cautious outlook

MPC Markets' Mark Gardner, for example, has a hold recommendation on CSL shares (courtesy of The Bull).

"The biotechnology giant generated revenue of $US8.470 billion in the first half of fiscal year 2025, up 5% at constant currency on the prior corresponding period," Gardner said.

Despite his hold recommendation, Gardner noted the solid growth CSL achieved over the half year in its core financial metrics.

He said:

Net profit after tax of $US2.043 billion at constant currency was up 7%. Key product segments demonstrated strong growth, with immunoglobulin product sales up 15%. Albumin sales increased 9% and haemophilia product sales increased 11%.

The company's gross margin improved by 170 basis points, reflecting operational efficiency.

What's the growth outlook for CSL shares?

For the full year FY 2025, management is forecasting year on year revenue growth of 5% to 7% on a constant currency basis.

CSL expects fiscal year 2025 net profit after tax and amortisation (NPATA) to be in the range of US$3.2 billion to US$3.3 billion on a constant currency basis. That equates to profit growth of approximately 10% to 13%.

CSL shares are down 7% over the past year, not including dividends.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »